Generated Narrative: PublicationRecord 179622 version: 23; Last updated: 2025-10-13 12:34:35+0000 Profile: JournalArticleCitation ArtifactPublicationStatus: Active url: https://fevir.net/resources/PublicationRecord/179622 identifier: FEvIR Object Identifier/179622, https://pubmed.ncbi.nlm.nih.gov/26002607 title: 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. status: Active author: Computable Publishing®: MEDLINE-to-FEvIR Converter: publisher: Computable Publishing LLC contact: support@computablepublishing.com description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide. UseContexts - Code Value[x] * Citation Classification Type: fevir-platform-use (FEvIR Platform Use) Medline Base copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/ approvalDate: 2016-04-21 lastReviewDate: 2024-05-16 classification type: Citation Source classifier: MEDLINE classification type: MEDLINE Citation Owner classifier: National Library of Medicine, Index Section currentState: Medline Citation Status of Medline, PubMed PublicationStatus of ppublish statusDate activity: PubMed Pubstatus of Received period: ?? --> 2015-03-21 statusDate activity: PubMed Pubstatus of Accepted period: ?? --> 2015-05-13 statusDate activity: PubMed Pubstatus of Entrez period: ?? --> 2015-05-24 06:00:00+0000 statusDate activity: PubMed Pubstatus of Pubmed period: ?? --> 2015-05-24 06:00:00+0000 statusDate activity: PubMed Pubstatus of Medline period: ?? --> 2016-04-22 06:00:00+0000 statusDate activity: PubMed Pubstatus of PMC release period: ?? --> 2016-08-01 citedArtifact identifier: https://pubmed.ncbi.nlm.nih.gov/26002607, https://www.ncbi.nlm.nih.gov/pmc//PMC4511224, https://doi.org/10.1093/annonc/mdv245, pii/S0923-7534(19)31866-6 Titles - Type Language Text * Primary title English Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Abstracts - Type Text Copyright * Primary human use Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of patient survival. The GETUG-AFU-15 and CHAARTED studies both assessed the efficacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic hormone-naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (∼75%) and patients who developed metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUG-AFU-15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone. The GETUG-AFU-15 did not find a significant difference in the primary end point of overall survival (OS) {hazard ratio (HR) 0.9 [95% confidence interval (CI) 0.7-1.2]; P = 0.44} for ADT plus docetaxel versus ADT alone. The CHAARTED study met the primary end point of OS [HR 0.61 (95% CI 0.47-0.80); P = 0.0003], and in a subset analysis reported the greatest improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45-0.81); P = 0.0006]. The following article debates the results from the GETUG-AFU-15 and CHAARTED studies and asks whether medical practice should be changed for patients with metastatic hormone-naive prostate cancer based on the results of one positive study. © The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. relatesTo type: Cites classifier: Journal Article citation: Wu JN, Fish KM, Evans CP et al. . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2013; 120(6): 818–823. target: https://pubmed.ncbi.nlm.nih.gov/24258693/ relatesTo type: Cites classifier: Journal Article citation: Center MM, Jemal A, Lortet-Tieulent J et al. . International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6): 1079–1092. target: https://pubmed.ncbi.nlm.nih.gov/22424666/ relatesTo type: Cites classifier: Journal Article citation: Cullen J, Elsamanoudi S, Brassell SA et al. . The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7. target: https://pubmed.ncbi.nlm.nih.gov/22529743/ relatesTo type: Cites classifier: Journal Article citation: Patrikidou A, Loriot Y, Eymard J-C et al. . Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014; 17(4): 348–352. target: https://pubmed.ncbi.nlm.nih.gov/25311767/ relatesTo type: Cites citation: Sweeney C, Carducci MA, Eisenberger MA et al. . Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol 2014; (Suppl 4): Abstr 7560. relatesTo type: Cites classifier: Journal Article citation: Gravis G, Fizazi K, Joly F et al. . Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14(2): 149–158. target: https://pubmed.ncbi.nlm.nih.gov/23306100/ relatesTo type: Cites classifier: Journal Article citation: Ahmed M, Li L-C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013; 20(4): 362–371. target: https://pubmed.ncbi.nlm.nih.gov/23163774/ relatesTo type: Cites classifier: Journal Article citation: Tannock IF, de Wit R, Berry WR et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512. target: https://pubmed.ncbi.nlm.nih.gov/15470213/ relatesTo type: Cites classifier: Journal Article citation: Berthold DR, Pond GR, Soban F et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242–245. target: https://pubmed.ncbi.nlm.nih.gov/18182665/ relatesTo type: Cites classifier: Journal Article citation: Petrylak DP, Tangen CM, Hussain MHA et al. . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–1520. target: https://pubmed.ncbi.nlm.nih.gov/15470214/ relatesTo type: Cites citation: Gravis G, Boher J-M, Joly F et al. . Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial. J Clin Oncol 2015; (GU suppl): abstr 140. relatesTo type: Cites citation: Sweeney C, Chen Y-H, Carducci MA et al. . Impact on overall survival with chemohormonal therapy versus hormone therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32(5s): abstr LBA2. relatesTo type: Cites classifier: Journal Article citation: Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2014; 65(6): 1198–1204. target: https://pubmed.ncbi.nlm.nih.gov/23910941/ relatesTo type: Cites classifier: Journal Article citation: Harris WP, Mostaghel EA, Nelson PS, Montgomery RB. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76–85. target: https://pubmed.ncbi.nlm.nih.gov/19198621/ relatesTo type: Cites classifier: Journal Article citation: van Soest RJ, van Royen ME, de Morrée ES et al. . Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49(18): 3821–3830. target: https://pubmed.ncbi.nlm.nih.gov/24200698/ relatesTo type: Cites classifier: Journal Article citation: Mezynski J, Pezaro C, Bianchini D et al. . Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23(11): 2943–2947. target: https://pubmed.ncbi.nlm.nih.gov/22771826/ relatesTo type: Cites classifier: Journal Article citation: Nakouzi Al N, Le Moulec S, Albiges L et al. . Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014; 66: e71–e72. target: https://pubmed.ncbi.nlm.nih.gov/24837187/ relatesTo type: Cites classifier: Journal Article citation: Payne H, Bahl A, Mason M et al. . Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; 110(5): 658–667. target: https://pubmed.ncbi.nlm.nih.gov/22429837/ relatesTo type: Cites classifier: Journal Article citation: Droz J-P, Aapro M, Balducci L et al. . Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15(9): e404–e414. target: https://pubmed.ncbi.nlm.nih.gov/25079103/ relatesTo type: Cites classifier: Journal Article citation: Stone P, Hardy J, Huddart R et al. . Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36(9): 1134–1141. target: https://pubmed.ncbi.nlm.nih.gov/10854947/ relatesTo type: Cites classifier: Journal Article citation: Nguyen PL, Alibhai SMH, Basaria S et al. . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67(5): 825–836. target: https://pubmed.ncbi.nlm.nih.gov/25097095/ relatesTo type: Cites classifier: Journal Article citation: Loriot Y, Fizazi K. Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur Urol 2013; 63(6): 983–985. target: https://pubmed.ncbi.nlm.nih.gov/23395593/ relatesTo type: Cites classifier: Journal Article citation: Gerritse FL, Meulenbeld HJ, Roodhart JML et al. . Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013; 49(15): 3176–3183. target: https://pubmed.ncbi.nlm.nih.gov/23849828/ relatesTo type: Cites classifier: Journal Article citation: Fizazi K, Abrahamsson P-A, Ahlgren G et al. . Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015; 67(5): 904–912. target: https://pubmed.ncbi.nlm.nih.gov/25218582/ relatesTo type: Cites classifier: Journal Article citation: Eisenberger MA, Blumenstein BA, Crawford ED et al. . Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–1042. target: https://pubmed.ncbi.nlm.nih.gov/9761805/ relatesTo type: Cites classifier: Journal Article citation: Crawford ED, Eisenberger MA, McLeod DG et al. . A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 419–424. target: https://pubmed.ncbi.nlm.nih.gov/2503724/ relatesTo type: Cites classifier: Journal Article citation: Hussain M, Tangen CM, Berry DL et al. . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368(14): 1314–1325. target: https://pubmed.ncbi.nlm.nih.gov/23550669/ relatesTo type: Cites classifier: Journal Article citation: Millikan RE, Wen S, Pagliaro LC et al. . Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26(36): 5936–5942. target: https://pubmed.ncbi.nlm.nih.gov/19029421/ relatesTo type: Cites classifier: Journal Article citation: Tait C, Moore D, Hodgson C et al. . Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114(6b): E70–E73. target: https://pubmed.ncbi.nlm.nih.gov/24589330/ relatesTo type: Cites classifier: Journal Article citation: Gravis G, Boher J-M, Fizazi K et al. . Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass Model and development of a novel simplified prognostic model. Eur Urol 2014. Sep 29 [epub ahead of print], doi: 10.1016/j.eururo.2014.09.022. target: https://pubmed.ncbi.nlm.nih.gov/25277272/ relatesTo type: Cites classifier: Journal Article citation: James ND, Spears MR, Clarke NW et al. . Survival with newly diagnosed metastatic prostate cancer in the ‘docetaxel era’: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67(6): 1028–1038. target: https://pubmed.ncbi.nlm.nih.gov/25301760/ relatesTo type: Cites classifier: Journal Article citation: Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57(2): 229–233. target: https://pubmed.ncbi.nlm.nih.gov/9000560/ relatesTo type: Cites classifier: Journal Article citation: Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253–265. target: https://pubmed.ncbi.nlm.nih.gov/15057285/ relatesTo type: Cites classifier: Journal Article citation: Mercader M, Sengupta S, Bodner BK et al. . Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007; 99(1): 60–67. target: https://pubmed.ncbi.nlm.nih.gov/17227493/ relatesTo type: Cites classifier: Journal Article citation: Ioannidis J. Why most published research findings are false. PLoS Med 2005; 2(8): e124. target: https://pubmed.ncbi.nlm.nih.gov/16060722/ relatesTo type: Cites classifier: Journal Article citation: Templeton AJ, Vera-Badillo FE, Wang L et al. . Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24(12): 2972–2977. target: https://pubmed.ncbi.nlm.nih.gov/24126362/ relatesTo type: Cites classifier: Journal Article citation: Gravis G, Marino P, Joly F et al. . Patients self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 2014; 50(5): 953–962. target: https://pubmed.ncbi.nlm.nih.gov/24424105/ publicationForm publishedIn type: Periodical identifier: Electronic ISSN Type/1569-8041, ISOAbbreviation/Ann Oncol, ISSN Linking/0923-7534, Medline Title Abbreviation/Ann Oncol, NLM Unique ID/9007735 title: Annals of oncology : official journal of the European Society for Medical Oncology publisherLocation: England citedMedium: Internet volume: 26 issue: 8 articleDate: 2015-08 pageString: 1660-7 publicationForm citedMedium: Internet without issue articleDate: 2015-05-22 webLocation classifier: Abstract url: https://pubmed.ncbi.nlm.nih.gov/26002607/ webLocation classifier: DOI Based url: https://doi.org/10.1093/annonc/mdv245 classification type: Publishing Model classifier: Print Electronic classification type: Keyword artifactAssessment: Keywords provided by NOTNLM classification type: Chemical classifier: Androgen Antagonists, Taxoids, Docetaxel, Gonadotropin-Releasing Hormone classification type: MeSH heading artifactAssessment: ArtifactAssessment: artifact[x] = this resource classification type: Publication type classifier: Journal Article, Research Support, Non-U.S. Gov't, Review classification type: Knowledge Artifact Type classifier: Journal Article artifactAssessment: Classifier added by Computable Publishing LLC classification type: Citation subset classifier: IM contributorship complete: true entry contributor: Fizazi K forenameInitials: K affiliation: Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Paris, France. entry contributor: Jenkins C forenameInitials: C affiliation: Med Ed, RMC, Exeter, UK. entry contributor: Tannock IF forenameInitials: IF affiliation: Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada ian.tannock@uhn.ca. Generated Narrative: ArtifactAssessment #keywords0 artifact: PublicationRecord 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. content classifier: ADT content classifier: de novo metastatic content classifier: docetaxel content classifier: hormone-naive content classifier: prostate Generated Narrative: Practitioner #contributor0 name: K Fizazi Generated Narrative: Practitioner #contributor1 name: C Jenkins Generated Narrative: Practitioner #contributor2 name: I F Tannock Generated Narrative: ArtifactAssessment #meshHeading0 artifact: PublicationRecord 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. content type: components (if present) include qualifier codings classifier: Androgen Antagonists freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: administration & dosage Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Antineoplastic Combined Chemotherapy Protocols freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: therapeutic use Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Bone Neoplasms freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: drug therapy Components - Type Classifier * is Major topic Yes component type: qualifier classifier: secondary Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Disease Progression freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Disease-Free Survival freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Docetaxel freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Gonadotropin-Releasing Hormone freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: agonists Components - Type Classifier * is Major topic Yes content type: components (if present) include qualifier codings classifier: Humans freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Male freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Orchiectomy freeToShare: true Components - Type Classifier * qualifier is Major topic content type: components (if present) include qualifier codings classifier: Proportional Hazards Models freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Prostatic Neoplasms freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: drug therapy Components - Type Classifier * is Major topic Yes component type: qualifier classifier: pathology Components - Type Classifier * is Major topic No content type: components (if present) include qualifier codings classifier: Standard of Care freeToShare: true Components - Type Classifier * qualifier is not a major topic content type: components (if present) include qualifier codings classifier: Taxoids freeToShare: true component type: qualifier classifier: is not a major topic component type: qualifier classifier: administration & dosage Components - Type Classifier * is Major topic No
components (if present) include qualifier codings
Antineoplastic Combined Chemotherapy Protocols
26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
Computable Publishing®: MEDLINE-to-FEvIR Converter
This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
National Library of Medicine, Index Section
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
Following the results of the TAX-327 study, questions have been raised as to whether administering chemotherapy to men with prostate cancer before symptomatic disease progression when receiving standard hormonal treatment can improve the duration and quality of patient survival. The GETUG-AFU-15 and CHAARTED studies both assessed the efficacy and tolerability of androgen deprivation therapy (ADT) with or without docetaxel in men with metastatic hormone-naive prostate cancer. Both studies included a mix of patients with de novo metastatic disease (∼75%) and patients who developed metastases following treatment of localized disease. A short course of ADT was allowed in both trials prior to accrual. Key differences between the two studies include the number of patients with high-volume metastases (GETUG-AFU-15: 52%; CHAARTED: 65%) and number of docetaxel cycles (GETUG-AFU-15: up to nine cycles; CHAARTED six cycles). Both studies reported an improvement in progression-free survival with docetaxel plus ADT versus ADT alone. The GETUG-AFU-15 did not find a significant difference in the primary end point of overall survival (OS) {hazard ratio (HR) 0.9 [95% confidence interval (CI) 0.7-1.2]; P = 0.44} for ADT plus docetaxel versus ADT alone. The CHAARTED study met the primary end point of OS [HR 0.61 (95% CI 0.47-0.80); P = 0.0003], and in a subset analysis reported the greatest improvement in OS for patients with high-volume disease [HR 0.60 (95% CI 0.45-0.81); P = 0.0006]. The following article debates the results from the GETUG-AFU-15 and CHAARTED studies and asks whether medical practice should be changed for patients with metastatic hormone-naive prostate cancer based on the results of one positive study.
© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Wu JN, Fish KM, Evans CP et al. . No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 2013; 120(6): 818–823.
Center MM, Jemal A, Lortet-Tieulent J et al. . International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6): 1079–1092.
Cullen J, Elsamanoudi S, Brassell SA et al. . The burden of prostate cancer in Asian nations. J Carcinog 2012; 11: 7.
Patrikidou A, Loriot Y, Eymard J-C et al. . Who dies from prostate cancer? Prostate Cancer Prostatic Dis 2014; 17(4): 348–352.
Sweeney C, Carducci MA, Eisenberger MA et al. . Chemohormonal therapy versus hormonal therapy for hormone naive newly metastatic prostate cancer: ECOG-led randomized trial. Ann Oncol 2014; (Suppl 4): Abstr 7560.
Gravis G, Fizazi K, Joly F et al. . Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 14(2): 149–158.
Ahmed M, Li L-C. Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 2013; 20(4): 362–371.
Tannock IF, de Wit R, Berry WR et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502–1512.
Berthold DR, Pond GR, Soban F et al. . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242–245.
Petrylak DP, Tangen CM, Hussain MHA et al. . Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513–1520.
Gravis G, Boher J-M, Joly F et al. . Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial. J Clin Oncol 2015; (GU suppl): abstr 140.
Sweeney C, Chen Y-H, Carducci MA et al. . Impact on overall survival with chemohormonal therapy versus hormone therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial. J Clin Oncol 2014; 32(5s): abstr LBA2.
Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol 2014; 65(6): 1198–1204.
Harris WP, Mostaghel EA, Nelson PS, Montgomery RB. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76–85.
van Soest RJ, van Royen ME, de Morrée ES et al. . Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer. Eur J Cancer 2013; 49(18): 3821–3830.
Mezynski J, Pezaro C, Bianchini D et al. . Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 2012; 23(11): 2943–2947.
Nakouzi Al N, Le Moulec S, Albiges L et al. . Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 2014; 66: e71–e72.
Payne H, Bahl A, Mason M et al. . Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities. BJU Int 2012; 110(5): 658–667.
Droz J-P, Aapro M, Balducci L et al. . Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol 2014; 15(9): e404–e414.
Stone P, Hardy J, Huddart R et al. . Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer 2000; 36(9): 1134–1141.
Nguyen PL, Alibhai SMH, Basaria S et al. . Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 2015; 67(5): 825–836.
Loriot Y, Fizazi K. Taxanes: still a major weapon in the armamentarium against prostate cancer. Eur Urol 2013; 63(6): 983–985.
Gerritse FL, Meulenbeld HJ, Roodhart JML et al. . Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study. Eur J Cancer 2013; 49(15): 3176–3183.
Fizazi K, Abrahamsson P-A, Ahlgren G et al. . Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 2015; 67(5): 904–912.
Eisenberger MA, Blumenstein BA, Crawford ED et al. . Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339(15): 1036–1042.
Crawford ED, Eisenberger MA, McLeod DG et al. . A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321(7): 419–424.
Hussain M, Tangen CM, Berry DL et al. . Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med 2013; 368(14): 1314–1325.
Millikan RE, Wen S, Pagliaro LC et al. . Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 2008; 26(36): 5936–5942.
Tait C, Moore D, Hodgson C et al. . Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114(6b): E70–E73.
Gravis G, Boher J-M, Fizazi K et al. . Prognostic factors for survival in noncastrate metastatic prostate cancer: validation of the Glass Model and development of a novel simplified prognostic model. Eur Urol 2014. Sep 29 [epub ahead of print], doi: 10.1016/j.eururo.2014.09.022.
James ND, Spears MR, Clarke NW et al. . Survival with newly diagnosed metastatic prostate cancer in the ‘docetaxel era’: data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol 2015; 67(6): 1028–1038.
Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997; 57(2): 229–233.
Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253–265.
Mercader M, Sengupta S, Bodner BK et al. . Early effects of pharmacological androgen deprivation in human prostate cancer. BJU Int 2007; 99(1): 60–67.
Ioannidis J. Why most published research findings are false. PLoS Med 2005; 2(8): e124.
Templeton AJ, Vera-Badillo FE, Wang L et al. . Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 2013; 24(12): 2972–2977.
Gravis G, Marino P, Joly F et al. . Patients self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 2014; 50(5): 953–962.
Annals of oncology : official journal of the European Society for Medical Oncology
Classifier added by Computable Publishing LLC
Department of Cancer Medicine, Gustave Roussy, University of Paris Sud, Paris, France.
Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada ian.tannock@uhn.ca.